Brink's receives CMA acceptance in principle of remedy for NCR Atleos acquisition

BRINKS CO

UK CMA accepted in principle Brink's proposed remedy to divest NoteMachine/TestLink UK, avoiding a CMA Phase 2 referral for the NCR Atleos acquisition.
Brink's said the NCR Atleos acquisition remains on track to close early in Q1 2027, with sale process for NoteMachine/TestLink UK progressing and prospective buyers engaged.
CEO Mark Eubanks said the remedy does not impact the $200 million in annual run-rate cost synergies expected within three years of closing the transaction.
Brink's and NCR Atleos trade on NYSE under BCO and NATL, respectively.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.